(Stroke. 2002;33:2664.)
© 2002 American Heart Association, Inc.
Original Contributions |
From the University of Michigan, Ann Arbor (P.A.S.); University of Cincinnati, Cincinnati, Ohio (A.M.P., J.E.); NIH/NINDS, Division of Diagnostics and Therapeutics, Bethesda, Md (L.A.D.); and St Joseph Mercy Hospital, Ann Arbor, Mich (S.M.F.).
Reprints requests to Phillip A. Scott, MD, Department of Emergency Medicine, University of Michigan, 1500 E Medical Center Dr, TC B1354, Box 0303, Ann Arbor, MI 48109. E-mail phillip.scott{at}umich.edu
Background and Purpose The emergency department (ED), as the point of first medical contact for many complaints referable to atrial fibrillation (AF) and a common source of primary care, occupies a unique position to identify AF patients at risk of stroke. This study evaluates that potential by determining the prevalence of AF in an ED population and assessing antithrombotic use in those patients with recurrent AF.
Methods This was a multicenter, retrospective, cross-sectional study of consecutive records of ED patients with AF identified by ECG between January and June 1998. American Heart Association and modified Stroke Prevention in Atrial Fibrillation criteria established high-risk patients and contraindications to anticoagulation, respectively.
Results We identified 866 records with ECG-proven AF in 78 787 patient visits for an estimated prevalence of 1.10% (95% CI, 1.03 to 1.17). We found that 556 records had a prior history of AF; of these, 221 (40%) used warfarin alone, 155 (28%) had antiplatelet therapy alone, 28 (5%) used both, and 152 (27%) had no antithrombotic therapy identified. Sixty-eight patients (12%; 95% CI, 0.10 to 0.15) were warfarin eligible and without antithrombotic therapy. An additional 64 (12%; 95% CI, 0.09 to 0.14) had antiplatelet therapy alone. In warfarin-eligible patients, no differences were identified between the anticoagulated and nonanticoagulated groups on the basis of age, sex, or race. Of patients on warfarin with a measured international normalized ratio, 61% (95% CI, 0.55 to 0.67) were outside the AHA-recommended range of 2.0 to 3.0.
Conclusions AF is a common finding in an ED population. Many are warfarin eligible and untreated or undertreated. Methods to increase anticoagulant use in this at-risk population warrant further investigation.
Key Words: anticoagulants atrial fibrillation stroke prevention
This article has been cited by other articles:
![]() |
R. Nieuwlaat, A. Capucci, A. J. Camm, S. B. Olsson, D. Andresen, D. W. Davies, S. Cobbe, G. Breithardt, J.-Y. Le Heuzey, M. H. Prins, et al. Atrial fibrillation management: a prospective survey in ESC Member Countries: The Euro Heart Survey on Atrial Fibrillation Eur. Heart J., November 2, 2005; 26(22): 2422 - 2434. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Murphy Maximizing current treatment options: exploring psychological barriers to change Eur. Heart J. Suppl., June 1, 2005; 7(suppl_E): E10 - E14. [Full Text] [PDF] |
||||
![]() |
B. Freestone, G. Y.H. Lip, P. A. Scott, and A. M. Pancioli Anticoagulation Uptake in Emergency Department Patients With Atrial Fibrillation Stroke, March 1, 2003; 34(3): 591 - 591. [Full Text] |
||||
![]() |
Inadequate Antithrombotic Treatment of Afib Journal Watch Cardiology, January 24, 2003; 2003(124): 5 - 5. [Full Text] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |